Alport Syndrome Clinical Trial
Official title:
Association Analysis Between Variants of COL4A3/COL4A4/COL4A5 and Alport Syndrome in the Han Chinese Population
Alport syndrome (AS) is caused by pathogenic variants in the type IV collagen genes COL4A3, COL4A4, and COL4A5. This study aims to enroll families and patients with a history of renal hematuria in 27 hospitals and detect these three genes for AS screening. This study also aims to analysis the effect of COL4A3/COL4A4/COL4A5 genotype on the development of kidney disease.
Alport syndrome (AS) is a genetically and phenotypically heterogeneous disorder caused by the mutations in the type IV collagen genes COL4A3, COL4A4, and COL4A5. In this study, next generation sequencing is used to screen AS on 8165 participants enrolled from families and patients with a history of renal hematuria in 27 hospitals of China Huadong Region. Genotype (variants in COL4A3/COL4A4/COL4A5)-phenotype (onset age of hearing loss, nephroticrange proteinuria, decline of eGFR, kidney survival and onset age of CKD5) correlations in AS were evaluated. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01696253 -
Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study
|
||
Terminated |
NCT01602835 -
Human Urine Sample Collection for Alport Nephropathy Biomarker Studies
|
N/A | |
Recruiting |
NCT00481130 -
Alport Syndrome Treatments and Outcomes Registry
|
||
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Recruiting |
NCT05448755 -
A Study of ELX-02 in Patients With Alport Syndrome
|
Phase 2 | |
Recruiting |
NCT06274489 -
A Study to Evaluate Setanaxib in Patients With Alport Syndrome
|
Phase 1/Phase 2 | |
Terminated |
NCT02855268 -
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome
|
Phase 2 | |
Recruiting |
NCT06226896 -
Effects of Dapagliflozin on Progression of Alport Syndrome
|
||
Recruiting |
NCT05927467 -
Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)
|
||
Terminated |
NCT03749447 -
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
|
Phase 3 | |
Completed |
NCT03019185 -
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL
|
Phase 2/Phase 3 | |
Recruiting |
NCT06425055 -
Vonafexor ALPort Syndrome Efficacy & Safety TRIAl-1 (ALPESTRIA-1)
|
Phase 2 | |
Completed |
NCT01705132 -
Urinary Biomarkers of the Progression of Alport Kidney Disease
|
N/A | |
Recruiting |
NCT05267262 -
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
|
Phase 2 | |
Completed |
NCT00622544 -
A Prospective Study of Microalbuminuria in Untreated Boys With Alport Syndrome
|
||
Recruiting |
NCT02378805 -
European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
|
||
Not yet recruiting |
NCT05655728 -
Treatment With Metformin in Chinese Children With Alport Syndrome
|
Phase 4 | |
Completed |
NCT00309257 -
Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT05133050 -
Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants
|
N/A |